Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Net Income | -80.11% | -80.11% | |||
| Total Depreciation and Amortization | -18.39% | -18.39% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 128.63% | 128.63% | |||
| Change in Net Operating Assets | 1,278.18% | 1,278.18% | |||
| Cash from Operations | -21.24% | -21.24% | |||
| Capital Expenditure | -38.46% | -38.46% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -38.46% | -38.46% | |||
| Total Debt Issued | -2.51% | -2.51% | |||
| Total Debt Repaid | 0.00% | 0.00% | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | -5.39% | -5.39% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -199.58% | -199.58% | |||